StreetInsider.com News Articles

Alamar Biosciences, Inc. (ALMR) Reports Q2 Loss of $0.22

Mon, 10 Aug 2026 17:15:09 -0400

Alamar Biosciences, Inc. (NASDAQ: ALMR) reported Q2 EPS of ($0.22). Revenue for the quarter came in at $29.4 million.

For earnings history and earnings-related data on Alamar Biosciences, Inc. (ALMR) click here.

Form 8-K Alamar Biosciences, Inc. For: Aug 10

Mon, 10 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260810/26897962.html

Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance

Mon, 10 Aug 2026 16:05:00 -0400

FREMONT, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended June 30, 2026.

Recent Highlights

Generated $29.4 million of total revenue for the second quarter of 2026, an increase of 82% as compared to the corresponding period of 2025
Launched the first commercial multiplexed blood-based immunoassay for eMTBR-tau, available in our NULISAseq™ Neuro 220 Panel and through our Technology Access Program, enabling scalable, non-invasive measurement of tau tangle burden
Expanded

Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance

Mon, 10 Aug 2026 16:05:00 -0400

Recent Highlights

Generated $29.4 million of total revenue for the second quarter of 2026, an increase of 82% as compared to the corresponding period of 2025
Launched the first commercial multiplexed blood-based immunoassay for eMTBR-tau, available in our NULISAseq™ Neuro 220 Panel and through our Technology Access Program, enabling scalable, non-invasive measurement of tau tangle burden
Expanded

Alamar Biosciences expands Alzheimer's proteomics deal to 140,000 samples

Mon, 10 Aug 2026 16:04:32 -0400

Alamar Biosciences (Nasdaq: ALMR) announced an expansion of its partnership with the Alzheimer's Disease Data Initiative and Gates Ventures, adding protein profiling of 86,000 plasma samples using its NULISAseq Neuro 220 panel, according to a press release.

The expanded agreement builds on a June 2025 announcement in which the partnership profiled more than 55,000 samples using Alamar's NULISA technology. Approximately 21,000 of the newly added samples are part of a national-scale proteomics initiative launched with research universities in mid-July 2026.

The combined dataset, projected for completion in 2027, is expected to encompass more than 140,000 samples collected across multiple geographies and cohorts,

Alamar Biosciences Expands Global Partnership with Alzheimer’s Disease Data Initiative and Gates Ventures

Mon, 10 Aug 2026 16:03:00 -0400

Expanded collaboration applies multiplex protein profiling across 86,000 additional samples, enabling researchers to move beyond single biomarkers toward a precision-medicine understanding of disease heterogeneity, subtypes, and trajectories

Combined dataset, projected for completion in 2027, expected to represent the largest study of neurodegenerative disease, encompassing more than 140,000 samples across diverse geographies and cohorts

FREMONT, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced an expansion of its strategic partnership with the Alzheimer's Disease Data Initiative and Gates

Alamar Biosciences Expands Global Partnership with Alzheimer’s Disease Data Initiative and Gates Ventures

Mon, 10 Aug 2026 16:03:00 -0400

FREMONT, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced an expansion of its strategic partnership with the Alzheimer's Disease Data Initiative and Gates

Alamar Biosciences launches immune profiling panel measuring 340 proteins

Tue, 28 Jul 2026 16:12:28 -0400

Alamar Biosciences, Inc. (Nasdaq: ALMR) announced the launch of its NULISAseq Immune 340 Panel, a multiplexed immune profiling product designed for translational research and drug development.

According to a company press release, the panel measures approximately 340 immune-related proteins simultaneously from a single sample. It expands on the company's existing NULISAseq Inflammation Panel 250 and is intended for use in research areas including cancer, cardiovascular and metabolic diseases, autoimmune diseases, and aging.

The company states the panel can detect immune mediators such as cytokines, chemokines, and cell death pathway markers that circulate at concentrations below the detection threshold of conventional immunoassays. Alamar

Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome

Tue, 28 Jul 2026 16:12:00 -0400

Expanded panel advances the understanding of immune system across translational and clinical research in cancer, cardiovascular and metabolic diseases, autoimmune diseases and aging

Highly sensitive multiplex measurement captures regulatory proteins, like checkpoint inhibitors, and low abundance targets that standard platforms routinely miss

FREMONT, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to advancing the early detection of disease, today announced the launch of the NULISAseq™ Immune 340 Panel, its broadest multiplexed immune profiling solution available for translational research and drug development. The panel expands on the

Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome

Tue, 28 Jul 2026 16:12:00 -0400

Expanded panel advances the understanding of immune system across translational and clinical research in cancer, cardiovascular and metabolic diseases, autoimmune diseases and aging

Highly sensitive multiplex measurement captures regulatory proteins, like checkpoint inhibitors, and low abundance targets that standard platforms routinely miss

Form 8-K Alamar Biosciences, Inc. For: Jul 15

Wed, 15 Jul 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260715/26774062.html

Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026

Tue, 14 Jul 2026 16:05:00 -0400

FREMONT, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it will report financial results for the second quarter 2026 after market close on Monday, August 10, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.alamarbio.com. The webcast will be archived and available for replay after the event.

Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026

Tue, 14 Jul 2026 16:05:00 -0400

Live audio of the webcast will be available on the “Investors” section of the company website at: www.alamarbio.com. The webcast will be archived and available for replay after the event.

Alamar Biosciences launches national Alzheimer's proteomics study

Mon, 13 Jul 2026 05:43:34 -0400

Alamar Biosciences (Nasdaq: ALMR) announced a partnership with researchers at Washington University in St. Louis, the University of Wisconsin, and Indiana University to conduct a national-scale proteomics study focused on Alzheimer's disease and related dementias.

The project will profile approximately 21,000 plasma samples collected from 10,000 Alzheimer's Disease Research Center participants across the United States using Alamar's NULISAseq Neuro 220 panel, which includes a newly added eMTBR-Tau assay for blood-based measurement of tau tangle burden alongside neurodegeneration and neuroinflammation biomarkers.

The initiative is co-led by Sarah Biber, PhD, at Washington University in St. Louis; Sterling Johnson, PhD, at the University of Wisconsin;

Alamar Biosciences launches national Alzheimer's proteomics study

Mon, 13 Jul 2026 05:43:34 -0400

The initiative is co-led by Sarah Biber, PhD, at Washington University in St. Louis; Sterling Johnson, PhD, at the University of Wisconsin;

Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases

Mon, 13 Jul 2026 02:30:00 -0400

National-scale initiative will profile ~21,000 plasma samples from 10,000 Alzheimer’s Disease and Related Dementias (ADRD) participants using Alamar Biosciences' NULISAseq™ Neuro 220 panel. | Resulting dataset will be publicly accessible, linked through National Alzheimer’s Coordinating Center IDs and open to AI-driven discovery through a national data challenge. | Project is part of the Consortium for Clarity in ADRD Research Through Imaging (CLARiTI) portfolio, leveraging academic, philanthropic, and data-sharing partnerships for large-scale biomarker discovery.

Fremont, CA, July 13, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to advancing the early detection of disease,

Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases

Mon, 13 Jul 2026 02:30:00 -0400

Fremont, CA, July 13, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to advancing the early detection of disease,

Alamar Biosciences NULISA data to appear in 140+ AAIC presentations

Fri, 10 Jul 2026 06:13:56 -0400

Alamar Biosciences, Inc. (Nasdaq: ALMR) announced that its NULISA platform will be featured in more than 140 poster and session presentations at the Alzheimer's Association International Conference (AAIC), taking place July 12–15 in London, according to a company press release.

The figure represents more than four times the number of presentations featuring NULISA data at the previous AAIC, the company said.

Alamar will host a workshop on July 14 titled "Beyond p-tau217: Expanding Alzheimer's Insights with Multiplex Protein Profiling," scheduled from 1:20 to 2:00 PM BST. The session will present data from the company's eMTBR-Tau and BD-pTau217 assays, which were measured alongside

Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer’s Biomarker Profiling

Fri, 10 Jul 2026 06:11:00 -0400

Company to host scientific workshop featuring emerging eMTBR-Tau and BD-pTau217 research data for Alzheimer’s disease detection and staging

Fremont, CA, July 10, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced that its NULISA™ platform will be featured in more than 140 poster and session presentations at the Alzheimer's Association International Conference (AAIC), taking place July 12-15 in London. The volume of data reflects widespread adoption of NULISA and ARGO™ HT technology among researchers studying Alzheimer’s and related dementias.

"With

Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer’s Biomarker Profiling

Fri, 10 Jul 2026 06:11:00 -0400

Company to host scientific workshop featuring emerging eMTBR-Tau and BD-pTau217 research data for Alzheimer’s disease detection and staging

"With

Form SCHEDULE 13D/A Alamar Biosciences, Inc. Filed by: Sands Capital Life Sciences Pulse Fund II, L.P.

Tue, 07 Jul 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260707/26742482.html

Alamar Biosciences launches eMTBR-Tau blood test for Alzheimer's

Tue, 07 Jul 2026 09:12:24 -0400

Alamar Biosciences (Nasdaq: ALMR) launched what it claims is the first commercial immunoassay for eMTBR-Tau, a plasma biomarker associated with tau tangle pathology in Alzheimer's disease, according to a company press release dated July 7, 2026.

The assay is available in the NULISAseq Neuro 220 multiplexed panel kits, compatible with the company's ARGO HT instruments, and as a single-plex assay through its Technology Access Program.

A definitive Alzheimer's diagnosis requires evidence of both amyloid plaques and tau neurofibrillary tangles. Until recently, only amyloid pathology could be assessed through blood testing, via pTau-217. Measuring tau tangle burden has historically required tau PET imaging,

Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease Research

Tue, 07 Jul 2026 09:12:00 -0400

eMTBR-Tau offers a non-invasive, blood-based measurement of the tau tangle burden, the core pathology associated with disease progression and cognitive decline in Alzheimer’s disease | Immunoassay for eMTBR-Tau is available in the NULISAseq™ Neuro 220 panel and as a single-plex assay through the Technology Access Program | Data to be featured in Alamar’s workshop at AAIC 2026

Fremont, CA, July 07, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today launched the first commercial eMTBR-Tau immunoassay, now available in the NULISAseq™

Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease Research

Tue, 07 Jul 2026 09:12:00 -0400

Form SCHEDULE 13G Alamar Biosciences, Inc. Filed by: SHERPA HEALTHCARE FUND II, L.P.

Thu, 02 Jul 2026 08:46:00 -0400

si-local-file:///var/storage/secattach/20260702/26724506.html